Tải bản đầy đủ - 0 (trang)
+) Đặc điểm mô bệnh học: típ nhú là típ hay gặp nhất trong nhóm u không xâm nhập (94,9%), típ thông thường hay gặp nhất trong nhóm u xâm nhập (91,4%). 76,6% các trường hợp là ung thư bàng quang chưa xâm nhập cơ. 69 ca u nhú giai đoạn pTa và pT1 có 55,1% u

+) Đặc điểm mô bệnh học: típ nhú là típ hay gặp nhất trong nhóm u không xâm nhập (94,9%), típ thông thường hay gặp nhất trong nhóm u xâm nhập (91,4%). 76,6% các trường hợp là ung thư bàng quang chưa xâm nhập cơ. 69 ca u nhú giai đoạn pTa và pT1 có 55,1% u

Tải bản đầy đủ - 0trang

72



+) Với các u tại chỗ và các u xâm nhập: CK20 dương tính lan tỏa tồn bộ

bề dày biểu mô ở cả 03 trường hợp u tại chỗ. CK20 dương tính ở 59,1% các

ca u xâm nhập cơ. Ki67 bộc lộ cao ở 77,3% (điểm cắt 10%).



TÀI LIỆU THAM KHẢO

1.



Torre L. A., Bray F., Siegel R. L. et al (2015). Global cancer statistics,

2012. CA: a cancer journal for clinicians, 65 (2), 87-108.



2.



Antoni S., Ferlay J., Soerjomataram I. et al (2017). Bladder cancer

incidence and mortality: a global overview and recent trends. European

urology, 71 (1), 96-108.



3.



Ferlay J., Soerjomataram I., Dikshit R. et al (2015). Cancer incidence

and mortality worldwide: sources, methods and major patterns in

GLOBOCAN 2012. Int J Cancer, 136 (5).



4.



Siegel R. L., Miller K. D. and Jemal A. (2016). Cancer statistics, 2016.

CA: a cancer journal for clinicians, 66 (1), 7-30.



5.



Mariotto A. B., Robin Yabroff K., Shao Y. et al (2011). Projections of

the cost of cancer care in the United States: 2010–2020. J Natl Cancer

Inst, 103 (2), 117-128.



6.



Leal J., Luengo-Fernandez R., Sullivan R. et al (2016). Economic burden

of bladder cancer across the European Union. European urology, 69 (3),

438-447.



7.



Pakzad R., Mohammadian-Hafshejani A., Mohammadian M. et al (2015).

Incidence and mortality of bladder cancer and their relationship with

development in Asia. Asian Pac J Cancer Prev, 16 (16), 7365-7374.



8.



Trịnh Tiên Phong (2010). Nghiên cứu đặc điểm mô bệnh học u biểu mô

đường niệu của bàng quang, Luận văn Thạc sĩ y học, Trường Đại học Y

Hà Nội



9.



Humphrey P. A., Ulbright T. M., Reuter V. E. et al (2016). WHO

classification of tumours of the urinary system and male genital organs,

4, International Agency for Research on Cancer, Lyon, 78-107



10.



Kumar V., Abbas A. K. and Aster J. C. (2013). Robbins Basic

Pathology E-Book, ninth, Elsevier Health Sciences, Philadelphia.



11.



Bostwick D. and Cheng L. (2014). Urologic Surgical Pathology, third,

Elsevier Saunder, Philadelphia, 230-276.



12.



Bộ môn Ngoại Trường Đại học Y Hà Nội (2006). Bài giảng bệnh học

ngoại khoa, Nhà xuất bản y học, Hà Nội, 134-139.



13.



Humphrey P. A., Moch H., Cubilla A. L. et al (2016). The 2016 WHO

classification of tumours of the urinary system and male genital organs

—part B: prostate and bladder tumours. European urology, 70 (1), 106119.



14.



Bertz S., Otto W., Denzinger S. et al (2014). Combination of CK20 and

Ki-67 immunostaining analysis predicts recurrence, progression, and

cancer-specific survival in pT1 urothelial bladder cancer. European

urology, 65 (1), 218-226.



15.



Chu P., Wu E. and Weiss L. M. (2000). Cytokeratin 7 and cytokeratin

20 expression in epithelial neoplasms: a survey of 435 cases. Modern

Pathology, 13 (9), 962.



16.



Nguyễn Văn Hưng và Nguyễn Thị Hồng Điệp (2010). Nghiên cứu mô

bệnh học, một số triệu chứng lâm sàng và cận lâm sàng của ung thư

biểu mơ tiết niệu. Tạp chí Y học thực hành (714), 4.



17.



Bộ môn Giải phẫu Trường Đại học Y Hà Nội (2006). Giải phẫu người,

Nhà xuất bản y học, Hà Nội, 291-293.



18.



Bộ môn Mô học Trường Đại học Y Hà Nội (2007). Phần Mô học. MôPhôi, Nhà xuất bản y học, Hà Nội, 197-199.



19.



Ross M. H. and Pawlina W. (2016). HISTOLOGY: A text and Atlas,

seventh, Wolters Kluwer, Philadelphia, 724-726.



20.



Babjuk M., Böhle A., Burger M. et al (2017). EAU guidelines on non–

muscle-invasive urothelial carcinoma of the bladder: update 2016.

European urology, 71 (3), 447-461.



21.



Zhou M., Netto G. J. and Epstein J. I. (2012). Uropathology, Elsevier

Health Sciences,



22.



Mostofi F. K. (1973). Histological typing of urinary bladder tumors.

International histological classification of tumors, 10, 15-34.



23.



Epstein J. I., Amin M. B., Reuter V. R. et al (1998). The World Health

Organization/International Society of Urological Pathology consensus

classification of urothelial (transitional cell) neoplasms of the urinary

bladder. Am J Surg Pathol, 22 (12), 1435-1448.



24.



Eble J., Sauter G., Epstein J. et al (2004). World Health Organization

classification of tumors. Tumors of the urinary system and genital

organs. Pathology and Genetics. Lyon: IARC Press,



25.



Jacobs B. L., Lee C. T. and Montie J. E. (2010). Bladder cancer in

2010: how far have we come? CA: a cancer journal for clinicians, 60

(4), 244-272.



26.



Edge S. (2010). American Cancer Society. AJCC cancer staging

handbook: from the AJCC cancer staging manual, New York: Springer,



27.



Pan C.-C., Chang Y.-H., Chen K.-K. et al (2010). Prognostic

significance of the 2004 WHO/ISUP classification for prediction of

recurrence, progression, and cancer-specific mortality of non–muscleinvasive urothelial tumors of the urinary bladder: a clinicopathologic

study of 1,515 cases. American journal of clinical pathology, 133 (5),

788-795.



28.



Cheng L., MacLennan G. T. and Lopez-Beltran A. (2012). Histologic

grading of urothelial carcinoma: a reappraisal. Human pathology, 43

(12), 2097-2108.



29.



Tuna B., Yörükoglu K., Düzcan E. et al (2011). Histologic grading of

urothelial papillary neoplasms: impact of combined grading (twonumbered grading system) on reproducibility. Virchows Archiv, 458 (6),

659.



30.



Lopez-Beltran A. and Montironi R. (2004). Non-invasive urothelial

neoplasms: according to the most recent WHO classification. European

urology, 46 (2), 170-176.



31.



Soukup V., Čapoun O., Cohen D. et al (2017). Prognostic Performance

and Reproducibility of the 1973 and 2004/2016 World Health

Organization Grading Classification Systems in Non–muscle-invasive

Bladder Cancer: A European Association of Urology Non-muscle

Invasive Bladder Cancer Guidelines Panel Systematic Review.

European urology,



32.



Kehr E. L. and Barletta J. A. (2017). Bladder Cancer. Pathology and

Epidemiology of Cancer, Springer, 523-541.



33.



Burger M., Denzinger S., Hartmann A. et al (2007). Mcm2 predicts

recurrence hazard in stage Ta/T1 bladder cancer more accurately than

CK20, Ki67 and histological grade. Br J Cancer, 96 (11), 1711.



34.



Ramos D., Navarro S., Villamón R. et al (2003). Cytokeratin expression

patterns in low‐grade papillary urothelial neoplasms of the urinary

bladder. Cancer, 97 (8), 1876-1883.



35.



Burger M., van der Aa M. N., van Oers J. M. et al (2008). Prediction of

progression of non–muscle-invasive bladder cancer by WHO 1973 and

2004 grading and by FGFR3 mutation status: a prospective study.

European urology, 54 (4), 835-844.



36.



Habuchi T., Marberger M., Droller M. J. et al (2005). Prognostic

markers for bladder cancer: International Consensus Panel on bladder

tumor markers. Urology, 66 (6), 64-74.



37.



Tsuji M., Kojima K., Murakami Y., eyal et al (1997). Prognostic value

of Ki‐67 antigen and p53 protein in urinary bladder cancer:

immunohistochemical analysis of radical cystectomy specimens. BJU

International, 79 (3), 367-372.



38.



Rudman S. M. and Crawley D. (2017). Epidemiology of Bladder

Cancer. Pathology and Epidemiology of Cancer, Springer, 511-522.



39.



Bệnh viện K (2016). Hướng dẫn chẩn đoán và điều trị một số bệnh ung

thư thường gặp, Nhà xuất bản y học, Hà Nội, 261-263.



40.



Chang S. S., Boorjian S. A., Chou R. et al (2016). Diagnosis and

treatment of non-muscle invasive bladder cancer: AUA/SUO guideline.

J Urol, 196 (4), 1021-1029.



41.



Lopez-Beltran A., Bassi P., Pavone-Macaluso M. et al (2004). Handling

and pathology reporting of specimens with carcinoma of the urinary

bladder, ureter, and renal pelvis. European urology, 45 (3), 257-266.



42.



Bộ Y Tế (2013). Hướng dẫn qui trình kỹ thuật chuyên ngành giải phẫu

bệnh - tế bào học, Hà Nội, 132-135.



43.



Harnden P., Mahmood N. and Southgate J. (1999). Expression of

cytokeratin 20 redefines urothelial papillomas of the bladder. The

Lancet, 353 (9157), 974-977.



44.



Paner



G.



P.,



Annaiah



C.,



Gulmann



C.



et



al



(2014).



Immunohistochemical evaluation of novel and traditional markers

associated with urothelial differentiation in a spectrum of variants of

urothelial carcinoma of the urinary bladder. Human pathology, 45 (7),

1473-1482.



45.



Stepan A., Simionescu C., Margaritescu C. et al (2011). P16, c-erbB2

and Ki67 immunoexpression in urothelial carcinomas of the bladder.

Rom J Morphol Embryol, 52 (2), 653-658.



46.



Canter D., Guzzo T., Resnick M. et al (2008). The presence of

lymphovascular invasion in radical cystectomy specimens from patients

with urothelial carcinoma portends a poor clinical prognosis. BJU

International, 102 (8), 952-957.



47.



Cheng L., Neumann R. M., Weaver A. L. et al (2000). Grading and

staging of bladder carcinoma in transurethral resection specimens:

correlation with 105 matched cystectomy specimens. American journal

of clinical pathology, 113 (2), 275-279.



48.



Hautmann R. E., de Petriconi R. C., Pfeiffer C. et al (2012). Radical

cystectomy for urothelial carcinoma of the bladder without neoadjuvant

or adjuvant therapy: long-term results in 1100 patients. European

urology, 61 (5), 1039-1047.



49.



Brimo F., Wu C., Zeizafoun N. et al (2013). Prognostic factors in T1

bladder urothelial carcinoma: the value of recording millimetric depth

of invasion, diameter of invasive carcinoma, and muscularis mucosa

invasion. Human pathology, 44 (1), 95-102.



50.



Wang Z. H., Li Y. Y., Hu Z. Q. et al (2012). Does urothelial cancer of

bladder behave differently in young patients? Chinese medical journal,

125 (15), 2643-2648.



51.



Paner G. P., Zehnder P., Amin A. M. et al (2011). Urothelial neoplasms

of the urinary bladder occurring in young adult and pediatric patients: a

comprehensive review of literature with implications for patient

management. Advances in anatomic pathology, 18 (1), 79-89.



52.



Fine S. W., Humphrey P. A., Dehner L. P. et al (2005). Urothelial

neoplasms in patients 20 years or younger: a clinicopathological

analysis using the world health organization 2004 bladder consensus

classification. The Journal of urology, 174 (5), 1976-1980.



53.



Wild P., Giedl J., Stoehr R. et al (2007). Genomic aberrations are rare

in urothelial neoplasms of patients 19 years or younger. The Journal of

pathology, 211 (1), 18-25.



54.



Nakagawa T., Hara T., Kawahara T. et al (2013). Prognostic risk

stratification of patients with urothelial carcinoma of the bladder with

recurrence after radical cystectomy. The Journal of urology, 189 (4),

1275-1281.



55.



Horstmann M., Witthuhn R., Falk M. et al (2008). Gender-specific

differences in bladder cancer: a retrospective analysis. Gender

medicine, 5 (4), 385-394.



56.



Hoke G. P., Stone B. A., Klein L. et al (1999). The influence of gender

on incidence and outcome of patients with bladder cancer in Harlem.

Journal of the National Medical Association, 91 (3), 144.



57.



Quirk J. T., Li Q., Natarajan N. et al (2004). Cigarette smoking and the

risk of bladder cancer in men and women. Tobacco induced diseases, 2

(3), 141.



58.



Gupta P., Jain M., Kapoor R. et al (2009). Impact of age and gender on

the clinicopathological characteristics of bladder cancer. Indian journal

of urology: IJU: journal of the Urological Society of India, 25 (2), 207.



59.



Madeb R. and Messing E. M. (2004). Gender, racial and age

differences in bladder cancer incidence and mortality. Urologic

Oncology: Seminars and Original Investigations, 22 (2), 86-92.



60.



Fajkovic H., Halpern J. A., Cha E. K. et al (2011). Impact of gender on

bladder cancer incidence, staging, and prognosis. World journal of

urology, 29 (4), 457-463.



61.



Scosyrev E., Noyes K., Feng C. et al (2009). Sex and racial differences

in bladder cancer presentation and mortality in the US. Cancer, 115 (1),

68-74.



62.



Henning A., Wehrberger M., Madersbacher S. et al (2013). Do

differences in clinical symptoms and referral patterns contribute to the

gender gap in bladder cancer? BJU international, 112 (1), 68-73.



63.



Dobbs R. W., Hugar L. A., Revenig L. M. et al (2014). Incidence and

clinical characteristics of lower urinary tract symptoms as a presenting

symptom for patients with newly diagnosed bladder cancer.

International braz j urol, 40 (2), 198-203.



64.



Lopez-Beltran A. (2008). Bladder cancer: clinical and pathological profile.

Scandinavian journal of urology and nephrology, 42 (sup218), 95-109.



65.



Geavlete P. A. (2016). Endoscopic Diagnosis and Treatment in Urinary

Bladder Pathology: Handbook of Endourology, Academic Press,



66.



Naito S., Algaba F., Babjuk M. et al (2016). The Clinical Research

Office



of



the



Endourological



Society



(CROES)



Multicentre



Randomised Trial of Narrow Band Imaging–Assisted Transurethral

Resection of Bladder Tumour (TURBT) Versus Conventional White

Light Imaging–Assisted TURBT in Primary Non–Muscle-invasive

Bladder Cancer Patients: Trial Protocol and 1-year Results. European

urology, 70 (3), 506-515.

67.



Vukomanovic I., Colovic V., Soldatovic I. et al (2012). Prognostic

significance of tumor location in high-grade non-muscle-invasive

bladder cancer. Medical Oncology, 29 (3), 1916-1920.



68.



Adiyat K. T., Katkoori D., Soloway C. T. et al (2010). “Complete

transurethral resection of bladder tumor”: are the guidelines being

followed? Urology, 75 (2), 365-367.



69.



Divrik R. T., Şahin A. F., Yildirim Ü. et al (2010). Impact of routine

second transurethral resection on the long-term outcome of patients with

newly diagnosed pT1 urothelial carcinoma with respect to recurrence,

progression rate, and disease-specific survival: a prospective randomised

clinical trial. European urology, 58 (2), 185-190.



70.



Xylinas E., Kent M., Kluth L. et al (2013). Accuracy of the EORTC

risk tables and of the CUETO scoring model to predict outcomes in

non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer,

109 (6), 1460.



71.



Mariappan P., Zachou A. and Grigor K. M. (2010). Detrusor muscle in

the first, apparently complete transurethral resection of bladder tumour

specimen is a surrogate marker of resection quality, predicts risk of

early recurrence, and is dependent on operator experience. European

urology, 57 (5), 843-849.



72.



Reis L. O., Taheri D., Chaux A. et al (2016). Significance of a minor

high-grade component in a low-grade noninvasive papillary urothelial

carcinoma of bladder. Human pathology, 47 (1), 20-25.



73.



Lapham R. L., Grignon D., and Ro J. Y. (1997). Pathologic prognostic

parameters in bladder urothelial biopsy, transurethral resection, and

cystectomy specimens. In Seminars in diagnostic pathology (Vol. 14,

No. 2, pp. 109-122).



74.



Koyuncuer A. (2017). Histopathologic Evolution of Urothelial

Carcinoma Recurrence in Transurethral Resection of the Urinary



Bladder: 35 Consecutive Cases And Literature Review. Asian Pacific

journal of cancer prevention: APJCP, 18 (2), 459.

75.



Satoh E., Miyao N., Tachiki H. et al (2002). Prediction of muscle

invasion of bladder cancer by cystoscopy. European urology, 41 (2),

178-181.



76.



Kamat A. M., Hahn N. M., Efstathiou J. A. et al (2016). Bladder cancer.

The Lancet, 388 (10061), 2796-2810.



77.



Sylvester R. J., van der Meijden A., Witjes J. et al (2005). High-grade

Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology,

66 (6), 90-107.



78.



Wasco M. J., Daignault S., Zhang Y. et al (2007). Urothelial carcinoma

with divergent histologic differentiation (mixed histologic features)

predicts the presence of locally advanced bladder cancer when detected

at transurethral resection. Urology, 70 (1), 69-74.



79.



Lopez-Beltran A. and Cheng L. (2006). Histologic variants of urothelial

carcinoma: differential diagnosis and clinical implications. Human

pathology, 37 (11), 1371-1388.



80.



Amin M. B. (2009). Histological variants of urothelial carcinoma:

diagnostic, therapeutic and prognostic implications. Modern Pathology, 22

(S2), S96.



81.



Compérat E., Roupret M., Yaxley J. et al (2010). Micropapillary

urothelial carcinoma of the urinary bladder: a clinicopathological

analysis of 72 cases. Pathology, 42 (7), 650-654.



82.



Samaratunga H., and Khoo K. (2004). Micropapillary variant of

urothelial carcinoma of the urinary bladder; a clinicopathological and

immunohistochemical study. Histopathology, 45(1), 55-64.



Tài liệu bạn tìm kiếm đã sẵn sàng tải về

+) Đặc điểm mô bệnh học: típ nhú là típ hay gặp nhất trong nhóm u không xâm nhập (94,9%), típ thông thường hay gặp nhất trong nhóm u xâm nhập (91,4%). 76,6% các trường hợp là ung thư bàng quang chưa xâm nhập cơ. 69 ca u nhú giai đoạn pTa và pT1 có 55,1% u

Tải bản đầy đủ ngay(0 tr)

×